Currently, various sedative agents are widely used and researched for procedural sedation in EDs. Ensuring safe and effective sedation during painful procedures necessitates appropriate patient selection, a thorough understanding of drug safety profiles and awareness of potential patient–drug interactions. Remimazolam, a sedative previously evaluated in intensive care and anaesthesiology units, has seen more extensive exploration in ambulatory procedural sedation, particularly for endoscopic and dental procedures, than in ED settings.1–6

In their EMJ paper, van der Have et al present a research letter detailing their dual-centre experience with remimazolam for procedural sedation in EDs, primarily for …